Collaborations & Alliances, Trials & Filings

AbbVie, Enanta Show HCV Results

96% of patients show sustained virologic response to oral, Interferon-free combo

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Enanta Pharmaceuticals has posted results from the SAPPHIRE-I study, one of six Phase III studies being conducted by AbbVie for the treatment of hepatitis C virus (HCV) genotype 1 (GT1) infection, using a regimen containing Enanta’s lead protease inhibitor ABT-450. ABT-450 is part of AbbVie’s investigational three direct-acting antiviral (3D) regimen, consisting of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. The SAPPHIRE...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters